Firibastat in Treatment-resistant Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 515 participants.
Also called NCT04277884
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 515 participants
- Sponsor
- Registry
-
NCT04277884
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Czechia, France, Germany, Poland, Spain
- Registry status
- Completed
Technical summary
Registry record NCT04277884. Randomized; quadruple masking; primary purpose treatment. Start 2020-06-25 (actual); primary completion 2022-08-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Firibastat in Treatment-resistant Hypertension
- Acronym
- FRESH
- Condition
- Hypertension
- Intervention (Drug)
- Firibastat
- Intervention (Drug)
- Placebo
- Lead sponsor
- Quantum Genomics SA
Record details
- Record id
cardio:ct-nct04277884- Content hash
9395ba26788b186373dcc90f40b714910c985795ca5bad0625dbe7abed0daa7d